Investor Overview



Shareholder Tools


Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments against multi-drug resistant (MDR), gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI), bloodstream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). In 2013, the Centers for Disease Control and Prevention identified CRE as a “nightmare bacteria” and an immediate public health threat that requires “urgent and aggressive action”, and in 2017 the World Health Organization identified CRE as a Global Priority 1 Pathogen: Critical Need for Research and Development of New Antibiotics.

In addition to plazomicin, Achaogen is developing a second product candidate, C-Scape, an oral antibacterial that is a combination of an approved beta-lactam and an approved beta-lactamase inhibitor with the potential to treat patients with cUTI due to MDR pathogens.

NASDAQ: AKAO
11.13
+ 0.08 (0.72%)
4:00 PM ET on Dec 18, 2017
Delayed at least 20 minutes.